Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invicta DiagnosticNSE:INVICTA +3.88%22 Forward Dividend Yield % is 0.00% as of Aug. 20, 2026. GuruFocus rates NSE:INVICTA with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 61 Medical Diagnostics & Research companies, Invicta Diagnostic ranks worse than 1639342.62% on this metric.
As of today (2026-08-20), the Forward Annual Dividend Yield of Invicta Diagnostic is 0.00%.
As of today (2026-08-20), the Trailing Annual Dividend Yield of Invicta Diagnostic is 0.00%.
NSE:INVICTA's Forward Dividend Yield % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.97 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Invicta Diagnostic Forward Dividend Yield % Related Terms
NSE:INVICTA vs TMO, DHR, IDXX: Forward Dividend Yield % Comparison
For the Diagnostics & Research subindustry, Invicta Diagnostic's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invicta Diagnostic Forward Dividend Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invicta Diagnostic's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Invicta Diagnostic's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Invicta Diagnostic (NSE:INVICTA) has a Forward Dividend Yield % of 0.00% as of Aug. 20, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Invicta Diagnostic and its competitors. According to the industry distribution chart, Invicta Diagnostic ranks #999999 out of 61 companies in the Medical Diagnostics & Research industry.
Is Invicta Diagnostic's Forward Dividend Yield % too high?
Invicta Diagnostic's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Invicta Diagnostic ranks #999999 out of 61 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Invicta Diagnostic has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Invicta Diagnostic's Forward Dividend Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Invicta Diagnostic ranks #999999 out of 61 companies for Forward Dividend Yield %. This places Invicta Diagnostic in the lower half of its industry. The industry median Forward Dividend Yield % is 1.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Diagnostics & Research company?
The median Forward Dividend Yield % among Medical Diagnostics & Research companies is 1.97, based on 61 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Invicta Diagnostic and its competitors. For the Medical Diagnostics & Research industry, the median Forward Dividend Yield % is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invicta Diagnostic's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invicta Diagnostic stock overvalued right now?
Invicta Diagnostic (NSE:INVICTA) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Invicta Diagnostic's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Invicta Diagnostic (NSE:INVICTA), the current Forward Dividend Yield % is 0.00% as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invicta Diagnostic Ltd is engaged in the business of medical and diagnostic services and operates diagnostic centres providing medical testing and allied healthcare services in the Mumbai Metropolitan Region. The Company runs a diagnostic chain comprising seven diagnostic centres and one centralised laboratory across MMR in Maharashtra and operates under a hub and spoke model with a flagship hub in Thane, additional hub centres, spoke centres, and a centralised laboratory. Its service offerings include radiology and imaging, pathology and clinical laboratory tests, teleradiology, and services such as ultrasound, X Ray, CT scan, MRI scan, PET scan, and cardiac diagnostics, with patient convenience supported through home sample collection, house calls, and multiple report delivery options.
22GF Score
Get the complete analysis for NSE:INVICTA
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INVICTA has been successfully added to your 
